Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.54 |
| ▸ | PIM1 | P11309 | 2/20 | 0.54 |
| ▸ | PRKACA | P17612 | 2/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PAK4 | O96013 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | LTK | P29376 | 1/20 | 0.54 |
| ▸ | GRK5 | P34947 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30514630 | 0.86 | AURKA (0.73) | BCL2L1AURKADAPK3PIM1PRKACA | |
| SCHEMBL844094 | 0.86 | AURKA (0.73) | BCL2L1AURKADAPK3PIM1PRKACA | |
| SCHEMBL2009820 | 0.84 | DYRK1A (0.56) | BCL2L1AURKADAPK3PIM1PRKACA | |
| SCHEMBL28769185 | 0.84 | DAPK3 (0.76) | AURKADAPK3PIM1PRKACAGSK3A | |
| SCHEMBL160500 | 0.83 | CDK8 (0.49) | AURKADAPK3PIM1PRKACAGSK3A | |
| SCHEMBL10857362 | 0.83 | HDAC1 (0.60) | AURKADAPK3PIM1PRKACAGSK3A | |
| SCHEMBL2010041 | 0.80 | HDAC1 (0.49) | BCL2L1AURKADAPK3PIM1PRKACA | |
| SCHEMBL2176222 | 0.80 | HDAC1 (0.52) | AURKADAPK3PIM1PRKACAGSK3A | |
| SCHEMBL21470630 | 0.80 | DYRK1A (0.49) | BCL2L1AURKADAPK3PIM1PRKACA | |
| SCHEMBL20955265 | 0.80 | CYP2A6 (0.48) | BCL2L1AURKADAPK3PIM1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | claimed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | claimed |
| CN-1759095-A | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARM INC (US) | 2006-04-12 | — | — | CN | claimed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | claimed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| CN-115703736-B | Multi-target inhibitor targeting HDAC and NAD synthesis and application thereof | 中国海洋大学 | 2025-05-16 | — | — | CN | disclosed |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2025-03-27 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | OCEAN UNIVERSITY OF CHINA (CN) | 2024-10-03 | — | — | US | disclosed |
| CN-118715206-A | Novel HDAC inhibitors and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| EP-3480193-B1 | PYRAZOLE DERIVATIVES AS ALK5 INHIBITORS AND USES THEREOF | HANMI PHARMACEUTICAL CO LTD (KR) | 2024-05-29 | — | — | EP | disclosed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | disclosed |
| WO-2002100857-A1 | QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| US-4577014-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| US-4501739-A | BACTERICIDES, ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1985-02-26 | — | — | US | disclosed |
| US-4480098-A | Preparation of alkali metal thieno(furo)pyridines | ELI LILLY AND COMPANY (US) | 1984-10-30 | — | — | US | disclosed |
| EP-0074268-A2 | Improvements in or relating to thieno and furopyridinium-substituted cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1983-03-16 | — | — | EP | disclosed |
| EP-0074268-A2 | Improvements in or relating to thieno and furopyridinium-substituted cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1983-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | BCL2L1 2442/4885AURKA 3698/4885DAPK3 1962/4885 |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | BCL2L1 380/4885AURKA 4800/4885DAPK3 2282/4885 |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | NQO2, SLC10A1, CYP7A1 | BCL2L1 3741/4885AURKA 2952/4885DAPK3 3803/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | BCL2L1 2442/4885AURKA 3698/4885DAPK3 1962/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | BCL2L1 1439/4885AURKA 4367/4885DAPK3 632/4885 |
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | HDAC3, HDAC1, HDAC11 | BCL2L1 2395/4885AURKA 1133/4885DAPK3 2285/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | BCL2L1 647/4885AURKA 3928/4885DAPK3 822/4885 |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | BCL2L1 4313/4885AURKA 3182/4885DAPK3 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.